REFERENCES & BIBLIOGRAPHY

1**.Menozzi.G, Mosti.L, Fossa.P, Mattioli.F, Ghia.M,** (1997), ω-Dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity, J. Heterocycl. Chem. 34(3), 963-968.

2. **Sharma.PK, Sawnhney.SN, Gupta.A, Singh.GB, Bani.S,** (1998), Synthesis and antiinflammatory activity of some 3-(2-thiazolyl)-1,2-benzisothiazolesIndian, J. Chem., 37B, 376-381.

3. **Bridges.AJ,** (1999), The rationale and strategy used to develop a series of highly potent,Irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases, Curr.Med. Chem., 6(9), 825-843.

4. **Boschelli.DH,** (1999), Small molecule inhibitors of receptor tyrosine kinases, Drugs Future, 24(5), 515.

5. Naito.H, Sugimor.M, et.al., (1999), Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives, Chem. Pharm. Bull. 47(12) 1679—1684.

6. **Jordan.JD, Landau.EM, Iyengar.R**, (2000), Signaling networks:The origins of cellular multitasking, Cell,103(2), 193-200.

7. **Küçükgüzel.SG, Rollas.S, Erdeniz.H, Kiraz.M, Ekinci.AC, Vidin.A,** (2000), Synthesis, characterization and pharmacological properties of some 4-arylhydrazono-2-pyrazoline-5-one derivatives obtained from heterocyclic amines, Eur. J.Med. Chem., 35, 761.

8**. Adams.JA,** (2001) Kinetic and catalytic mechanisms of protein kinases. Chem. Rev, 101(8), 2271- 2790.

9. **Bebernitz.GR, Argentieri.G, Battle.B, Brennan.C, Balkan.B, Burkey.BF, Eckhardt.M, Gao.J, Kapa.P, Strohschein.RJ, Schuster.HF,Wilson.M, Xu.DD**, (2001), The Effect of 1,3-Diaryl-[1H]-pyrazole- 4-acetamides on Glucose Utilization in ob/ob Mice, J.Med.Chem. 44, 2601.

10. **Blume-Jensen.P, Hunter.T,** Oncogenic kinase signaling, (2001), Nature, 411(6835), 355- 365.

11. **Bridges AJ,** (2001), Chemical inhibitors of protein kinases. Chem Rev, 101, 2541–2572

12. **Dumas.J.** (2001), Growth factor receptor kinase inhibitors: recent progress and clinical, Current opinion in drug discovery & development, . Curr. Opin. Drug Discov.Dev 378-389

13. **Yarden.Y, Sliwkowski.MX,** (2001), Untangling the ErbB signalling network.Nat. Rev. Mol. Cell Biol., 2(2), 127-137.

14. **Druker BJ**, (2002), Perspectives on the development of a molecularly targeted agent. Cancer Cell, 1, 31–36.

15. **Quiroga.J, Hernandez.P, Insuassty.BR, Abonia.R, Cobo.J, Sanchez, A, Nogueras.M, Low,** (2002), Control of the Reaction Between 2-Aminobenzothiazoles and Mannich Bases: Synthesis of pyrido[2,1-b][1,3]benzothiazoles versus [1,3]benzothiazolo[2,3-b]quinazolines. J Chem Soc Perkin Trans1. J. N. J. Chem. Soc., Perkin Trans.1, 4, 555-559.

16. **Hutchinson.I, Jennings.SA, Vishnuvajjala.BR., Westwell.AD, Stevens.M**, (2002), Antitumor Benzothiazoles. 16.1 Synthesis and Pharmaceutical Properties of Antitumor 2-(4- aminophenyl)benzothiazole Amino Acid Prodrugs, J. Med. Chem., 45(3), 744.

17. **Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C, Franklin WA,** (2003), Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol; 21, 3798–3807.

18. **Sridhar.R, Perumal.PT, Etti.S, Shanmugam.G, Ponnuswamy.MN, Prabavathy.VR, Mathivanan.N** (2004), Design, synthesis and anti-microbial activity of 1H- pyrazole carboxylates, Bioorg.Med.Chem. Lett., 14(24), 6035-6040.

19. Tanitame.A, Oyamada.Y, Ofuji.K, Fujimoto.M, Iwai.N, Hiyama, Y, Suzuki.K, Ito.H, Wachi.M, Yamagishi.J, (2004), Synthesis and Antibacterial Activity of a Novel Series of Potent DNA Gyrase Inhibitors. Pyrazole Derivatives, J.Med.Chem., 47, 3693-3696.

20**. Chabner BA, Roberts TG,** (2005), Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer; 5(1), 65–72.

21**. Krause DS, Van Etten RA,** (2005), Tyrosine kinases as targets for cancer therapy. N Engl J Med., 353, 172–187.

22**. Park.HA, Lee.K, Park, SJ, Ahn.B, Lee.JC, Cho.HY, Lee.KI,** (2005), Identification of antitumor activity of pyrazole oxime ethers., Bioorg. Med. Chem. Lett 15(13), 3307-3312.

23. **Dayam.R, Aiello.F, Deng.JX, Wu.Y, Garofalo.A,Chen.XY, Neamati.NJ,** (2006), Discovery of Small molecule integrin αvβ3 Antagonists as novel anticancer agents J.Med. Chem, 49, 4526-4534.

24. **Al-Saadi.MS et.al.,** (2008), Synthesis and Biological Evaluation of Some 2,4,5-Trisubstituted thiazole derivatives as potential antimicrobial and anticancer agents, Arch. Pharm. Chem. Life Sci., 34 (1), 424-434.

25. **Hubbard.RD, Bamaung.NY, Fidanze.SD, Erickson.SA, Palazzo.F, Wilsbacher.** (2009), Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal

growth factor family of receptor tyrosine kinases, Bioorg. Med.Chem. Lett., 19, 1718.

26. **Kayagil.I, Demirayak.S**, (2009), Synthesis and anticancer activities of some thiazole derivatives, Phosphorus Sulfur and Silicon and the Related Elements Sulfur, 9, 2197-2207.

27. **Faidallah.H, Rostom.S, and Al-Saadi.M**, (2010), Synthesis and biological evaluation of some new substituted fused pyrazole ring systems as possible anticancer and antimicrobial agents, JKAU: Sci., 22 (1), 177-191.

28. **Farghaly.AR,** (2010), Synthesis of some new indole derivatives containing pyrazoles with potential antitumor activity, Arkivoc, 11, 177-187.

29. **Prassanna D, Vijendra.K., Vinaya.K, et.al**., (2010), Synthesis and identification of a new class of antileukemic agents containing 2-(arylcarboxamide)-(S)-6-amino-4,5,6,7- tetrahydrobenzo [d]thiazole, European Journal of Medicinal Chemistry, 45(11), 5331– 5336.

30.**Soares.M, Brito. A, Laranjo.M, et.al.,** (2010), Chiral 6-hydroxymethyl-1H,3H pyrrolo[1,2c]thiazoles: Novel antitumor DNA monoalkylating agents, European Journal of Medicinal Chemistry, 45, 4676-4681.

31. **Ahmedin Jemal, DVM, Bray. F, Center. MM, Ferlay. J, Ward. E, Forman. D,** (2011), Global Cancer Statistics, CA: A Cancer J. For Clin, 61(2),69–90

32. **Ghorab.MM et,al.,** (2011), Synthesis of Certain New thiazole derivatives bearing a sulfonamide moiety with expected anticancer and radiosensitizing activities, Journal of Materials Science and Engineering A 1, 684-691.

33. **Kaminskyy.D, Khyluk. D,Olexandr Vasylenko, et.al**., (2011), A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugate Sci Pharm. 79(4): 763–777.

34. **Lesyk.RB et.al.,** (2011), Thiazolidinone motif in anticancer drug discovery experience of DHLNMU medicinal chemistry scientific group, Biopolymers and Cell, 27(2), 107–117.

35. **Mohamed.A, Amr.AG, et.al**., (2011), Anticancer activities of some new synthesized thiazolo[3,2-a]pyrido[4,3-d]pyrimidine Derivatives, American Journal of Biochemistry and Biotechnology 7 (2), 43-54

36. **Romagnoli. R, Baraldi. PG, Cara. CL, et.al.,** (2011) One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole: A unique, highly active antimicrotubule agent.

37. **Zeinab. I, Fekria.S and Shaimaa .AM** (2011), Synthesis, antimicrobial, antitumour, activity of some 3,5-diaryl and 1,3,5 triaryl-2-pyrazoline derivatives, Journal of American Science, 7(10), 756-767.